Actavis, Valuation and Fairness Opinions
|
|
- Shannon Rice
- 5 years ago
- Views:
Transcription
1 Actavis, Valuation and Fairness Opinions Adopting the Rule of Reason Approach to Evaluate Brand/Generic Agreements Through Valuation and Fairness Opinions February 2015
2 FTC Reverse Payment Settlement Statistics Final Settlements Final Settlements Involving First Filers Potential Pay-for-Delay Potential Pay-for-Delay Involving First Filers Source: FTC FY 2013 Report on Branded Drug Firms Patent Settlements with Generic Competitors 2
3 Fairness Opinions A fairness opinion often takes the form of a letter prepared by an experienced appraiser, which states whether or not a transaction is fair from a financial point of view to a represented party as of a specific date and given a set of assumptions. 3
4 Typical Use Users of fairness opinions are primary decision makers responsible for recommending what is in the best interests of the represented party. Fairness opinions provide the judgment of an independent professional to assist in making a reasonable, economically fair business decision for the represented party. Fairness opinions do not address fairness from a legal point of view or recommend that the transaction be executed. 4
5 Reported WW Use of Fairness Opinions 1,200 1, to # of US Deals # of Non-US Deals Source: Thomson Reuters - Financial Advisors, Mergers & Acquisitions Review 5
6 WW Fairness Opinion Transaction Value $1,000,000 $900,000 $800,000 $700, to 2014 (Millions) $600,000 $500,000 $400,000 $300,000 $200,000 $100,000 $ US Deals Total Value Non-US Deals Total Value Source: Thomson Reuters - Financial Advisors, Mergers & Acquisitions Review 6
7 Use by Corporate Boards Of Directors Never Infrequently Occasionally Frequently Material consideration paid by controlling party f or services in a private entity 26.8% 25.0% 33.9% 14.3% Consideration received by holders of differing classes of stock 19.6% 14.3% 35.7% 30.4% Material consideration paid by controlling party f or services in a public entity 21.4% 21.4% 30.4% 26.8% Transfer of assets between multi -party owned private entities managed by related party 17.9% 17.9% 30.4% 33.9% Transfer of assets between public entities managed by related party 21.4% 12.5% 33.9% 32.1% Sale or merger of assets or equity (sell -side opinion) 12.7% 16.4% 29.1% 41.8% Acquisition of assets or equity (buy -side opinion) 10.9% 20.0% 36.4% 32.7% Source: FTI Capital Advisors 2014 Survey 7
8 Fairness Opinions Appraisal Basics Market Approach The Market Approach values assets based on comparable transactions between unrelated parties. Income Approach The Income Approach provides a systematic framework for estimating an asset s price based on the value of the benefits derived from the use of that asset. Cost Approach The cost approach values assets based on the cost to create and develop the assets. 8
9 Fairness Opinions in Pharma Deals Courts have discussed the need to establish the value of non-monetary terms contained in the settlement. Evidence of a fair value exchange can explain a potential reverse payment settlement, and show that any payment is not for a delay. Established principles used in valuations and fairness opinions can help answer these difficult questions regarding reverse payment settlements. 9
10 Pharma Fair Value Assessment Valuation of any non-monetary consideration: Distribution rights, supply and marketing agreements, settlement of separate litigation, etc. Assessment of the relationship between monetary and non-monetary consideration Comparison of monetary consideration to expected litigation costs Assessment of the relevant market, the parties market power, industry licensing norms, and comparable transactions 10
11 Pharmaceutical X Case Study Generic first-filer agrees: That Brand s X patent is valid and infringed To refrain from selling a Generic version of X, until 1 year before the patent expires To assist Brand in marketing and detailing X until Generic s entry To manufacture and supply X to Brand until patent expires Brand agrees: To pay $50M to Generic To permit Generic to begin selling a Generic version of X, 1 year before the patent expires To pay Generic 1% above fully loaded cost of supplied X purchased from Generic To dismiss the appeal in an unrelated patent case 11
12 Pharmaceutical X Case At First Glance Brand paid $50M and Generic agreed not to enter the market for several years. Must be Pay-for-Delay Or is it? 12
13 Pharmaceutical X Case Calculation of Value $50 M Cash Marketing Agreement Supply Agreement + Dismissal of Litigation Payment for Delay 13
14 Pharmaceutical X Case Calculation of Value Consideration Cash Marketing Agreement Supply Agreement + Dismissal of Litigation Payment for Delay Low Value $50M $27M $20M + $1 $4M High Value $50M $25M $18M + $1 $8M 14
15 Likelihood of Anticompetitive Effects Potential payment for delay: $4M to $8M Scale in relation to litigation costs: $5M to $10M of avoided litigation costs per party The similarity of the potential payment for delay and the avoided litigation costs indicates that the remaining payment is intended to save litigation costs and comports with typical settlement considerations Payment in relation to other services exchanged: The majority of value exchanged by the parties was for the other agreements and services in the settlement 15
16 Likelihood of Inducing Later Generic Entry Potential payment for delay: $4M to $8M Profits expected by Generic had it prevailed in suit: Generic expected to generate $25M in profit if it had launched the generic prior to the expiration of patent X Payment compared to potential profits: Comparing the size of the potential payment for delay to the Generic s expected profits indicates that the payment did not induce Generic to accept a later entry date 16
17 Potential Fair Value Assessment Opinion Most or all of the payment from Brand to Generic is explained by factors other than payment for delay. Settlement was primarily accounted for by the exchange of other valuable consideration and avoidance of continued and costly litigation. Fair value was exchanged by Brand and Generic. 17
18 When Might An Opinion Be Considered? Hatch-Waxman to Settlement Antitrust Litigation CRAFTING THE DEAL Advise on deal terms that will meet scrutiny and satisfy fair value assessment Support the final settlement with a fair value assessment DEFENDING THE DEAL Opine on the fair value of various elements of deal consideration Opine on the economic feasibility of an at-risk-launch 18
19
20 James E. Malackowski 200 West Madison 37 th Floor Chicago, IL (312) Ph (312) Fx
21
Reverse Payment Settlements in the Pharmaceutical Industry. Arti K. Rai Duke Patent Law Institute May 17, 2013
Reverse Payment Settlements in the Pharmaceutical Industry Arti K. Rai Duke Patent Law Institute May 17, 2013 Outline Background law, history Policy/legal arguments against payments (primarily US/FTC)
More informationAgreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 003 Summary of Agreements Filed in FY 007 A Report by the Bureau of Competition
More informationCLIENT ALERT FTC S PHARMACEUTICAL INDUSTRY REPORT FINDS SUBSTANTIAL INCREASE IN PATENT SETTLEMENTS WITH PAYMENTS TO GENERIC FIRMS
CLIENT ALERT FEBRUARY 007 FTC S PHARMACEUTICAL INDUSTRY REPORT FINDS SUBSTANTIAL INCREASE IN PATENT SETTLEMENTS WITH PAYMENTS TO GENERIC FIRMS On January 17, 007, the Federal Trade Commission (FTC) issued
More informationRecent Patent Settlement Case In Korean Pharmaceutical Industry
Recent Patent Settlement Case In Korean Pharmaceutical Industry Hwang Lee Professor Korea University School of Law Innovation, Competition & Regulation Law Center Background Importance of Generic Drugs
More informationBy object or by effect: revisiting pharmaceutical patent settlements after paroxetine
Agenda Advancing economics in business By object or by effect: revisiting pharmaceutical patent settlements after paroxetine Are patent settlement agreements in the pharmaceutical sector an infringement
More informationClient Alert. FTC Sues Cephalon for Reverse Payment Patent Settlements with Four Generic. the payments cause delayed entry by the generic firm.
Client Alert february 2008 FTC Sues Cephalon for Reverse Payment Patent Settlements with Four Generic Pharmaceutical Firms Last week, the Federal Trade Commission (FTC or commission) brought the latest
More informationSTATEMENT FOR THE RECORD GEORGE P. SLOVER CONSUMERS UNION BEFORE THE
STATEMENT FOR THE RECORD GEORGE P. SLOVER CONSUMERS UNION BEFORE THE SUBCOMMITTEE ON ANTITRUST, COMPETITION POLICY, AND CONSUMER RIGHTS COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ON PAY-FOR-DELAY
More informationLDD «Barcode» Postal Service: Please do not mark barcode Claim#: LDD-«Claim8» - «CkDig» «First1» «Last1» «Addr2» «Addr1» «City», «St» «Zip»
Lidoderm End-Payor Notice Administrator c/o KCC Class Action Services P.O. Box 43491 Providence, RI 02940-3491 LDD «Barcode» Postal Service: Please do not mark barcode Claim#: LDD-«Claim8» - «CkDig» «First1»
More informationCase 3:17-cv Document 1 Filed 01/23/17 Page 1 of 27
Case :-cv-00 Document Filed 0// Page of Markus H. Meier, D.C. Bar No. Bradley S. Albert, Md. Bar Jamie R. Towey, D.C. Bar No. Eric M. Sprague, N.Y. Bar Daniel W. Butrymowicz, N.Y. Bar Daniel S. Bradley,
More informationHealthcare Antitrust Issues
Quick Hit on Healthcare Antitrust Sponsored By The Association of Corporate Counsel, Health Law Committee September 10, 2013 Mark J. Horoschak, Partner WOMBLE CARLYLE SANDRIDGE & RICE, LLP Healthcare Antitrust
More informationAre Patent Settlements Anti-Competitive? The EU Perspective
Max Planck Institute for Intellectual Property and Competition Law Are Patent Settlements Anti-Competitive? The EU Perspective Josef Drexl 18 October 2013 1 Introduction: What makes the EU situation different?
More informationPurpose of the Hatch-Waxman Act
Purpose of the Hatch-Waxman Act The purpose of the Act was to make available more low cost generic drugs by establishing a generic drug approval process for pioneer drugs first approved after 1962. H.R.
More informationPART I: PHARMACEUTICAL PATENTS AND COMPETITION ISSUES
PART I: PHARMACEUTICAL PATENTS AND COMPETITION ISSUES CHAPTER 2 THE PERSPECTIVE OF LAW PART 8. REVERSE SETTLEMENTS IN THE EUROPEAN UNION AND THE UNITED STATES Damien Geradin, Douglas H. Ginsburg & Graham
More informationTrends in Merger Investigations and Enforcement at the U.S. Antitrust Agencies
CORNERSTONE RESEARCH Economic and Financial Consulting and Expert Testimony Trends in Merger Investigations and Enforcement at the U.S. Antitrust Agencies Fiscal Years 2006 2015 Second Edition Data as
More informationState of Transaction Opinions
State of Transaction Opinions Optimizing Opinion Defensibility The State of Transaction Opinions Report, written by FTI Capital Advisors, LLC ( FTICA ), presents the results of a survey covering the effectiveness
More informationFinance for the future of law. How Burford helps businesses
Finance for the future of law How Burford helps businesses Burford Capital is a pioneer in litigation funding. WALL STREET JOURNAL Burford [is] really innovating and expanding the way we think of litigation
More informationUNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA NOTICE OF CLASS CERTIFICATION AND PARTIAL PROPOSED BIOVAIL SETTLEMENT
UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA NOTICE OF CLASS CERTIFICATION AND PARTIAL PROPOSED BIOVAIL SETTLEMENT If You Bought Wellbutrin XL or its Generic Equivalent, You May
More informationInstitutional Equities
Company Update Institutional Equities Dr. Reddy s Laboratories 5 September 2017 Reuters: REDY.BO; Bloomberg: DRRD IN Suboxone Generic Opportunity To Be Lucrative, Can Sustain For Longer Time The district
More informationPatent Litigation + Competition Law Two Different Worlds? Public
Patent Litigation + Competition Law Two Different Worlds? 1 Public Overview Matthew Hall the Competition Law world Matthew Royle the Patent Litigation world George Moore the Real world...? 2 Public Overview
More informationPatenting Practices and Patent Settlement Agreements
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Patenting Practices and Patent Settlement Agreements
More informationEnglish - Or. English DIRECTORATE FOR FINANCIAL AND ENTERPRISE AFFAIRS COMPETITION COMMITTEE
Unclassified DAF/COMP/WD(2014)62 DAF/COMP/WD(2014)62 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 12-Jun-2014 English
More informationWhen Does A Little Equal Enough?
When Does A Little Equal Enough? Development and filing of an ANDA to market a generic drug requires many considerations. One important consideration concerns the evaluation of the patent landscape protecting
More information1st Report on the Monitoring of Patent Settlements (period: mid end 2009)
1st Report on the Monitoring of Patent Settlements (period: mid 2008 - end 2009) Published on 5 July 2010 1. Introduction (1) As announced in the Commission's Communication 1 concluding the pharmaceutical
More informationTARO PHARMACEUTICAL INDUSTRIES LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT
More informationApril 14, Statement of J Kyle Bass Chief Investment Officer, Hayman Capital Management, L.P.
April 14, 2015 Statement of J Kyle Bass Chief Investment Officer, Hayman Capital Management, L.P. U.S. House of Representatives Committee on the Judiciary Hearing: H.R. 9, The Innovation Act The Honorable
More informationImplications of the America Invents Act for Income Tax Patent Valuations
Income Tax Valuation Insights Implications of the America Invents Act for Income Tax Patent Valuations Ashley L. Reilly On September 16, 2011, President Obama signed into law the America Invents Act (the
More informationThe Interface Between Competition and Intellectual Property Law: A Canadian Perspective
The Interface Between Competition and Intellectual Property Law: A Canadian Perspective D. Jeffrey Brown Stikeman Elliott LLP May 3, 2011 www.stikeman.com Disclaimer The views expressed in this presentation
More informationEC Competition Law and Veterinary Medicines
EC Competition Law and Veterinary Medicines 5th Annual Conference Regulation of Veterinary Medicines in Europe, Prague 3-6 March 2009 Howard Rosenblatt Latham & Watkins operates as a limited liability
More informationAMPHASTAR PHARMACEUTICALS INC.; INTERNATIONAL MEDICATION SYSTEMS LTD., Plaintiffs-Appellants, v.
16-2113 IN THE United States Court of Appeals FOR THE FIRST CIRCUIT AMPHASTAR PHARMACEUTICALS INC.; INTERNATIONAL MEDICATION SYSTEMS LTD., Plaintiffs-Appellants, v. MOMENTA PHARMACEUTICALS, INC.; SANDOZ
More informationFor personal use only
INVESTOR PRESENTATION AUGUST 2012 CONTENTS FY2012 Highlights FY2012 Income Balance Sheet Dividend History Investment Portfolio Possible Completions FY2013 Track Record Client Group Future Outlook 2 FY2012
More informationQuo Vadis FTC?: The Meaning Of FTC Case Against Endo
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Quo Vadis FTC?: The Meaning Of FTC Case Against
More informationChapter 41 - Legal and Other Proceedings
Chapter 41 - Legal and Other Proceedings Authoritative Sources FAR 31.205-47 Costs Related to Legal and Other Proceedings FAR31.205-33 Professional and Consultant Service Costs FAR 31.204 Application of
More information'Brazil Cotton' Makes Trade Retaliation Operational
Portfolio Media, Inc. 648 Broadway, Suite 200 New York, NY 10012 www.law360.com Phone: +1 212 537 6331 Fax: +1 212 537 6371 customerservice@portfoliomedia.com 'Brazil Cotton' Makes Trade Retaliation Operational
More informationServices and Capabilities. Health Care
Services and Capabilities Health Care Our team of experts offers an unmatched combination of economic credentials, industry expertise, and testifying experience. Health Care and Antitrust Introduction/Overview
More informationIP ISSUES IN MERGERS & ACQUISITIONS
M&A ACADEMY IP ISSUES IN MERGERS & ACQUISITIONS Louis Beardell, James Carrigan, and Rachelle Dubow March 29, 2016 Key IP Issues in Mergers & Acquisitions I. IP due diligence: scope, validity, ownership,
More informationThe Annual Report and Accounts and Notice of AGM can also be viewed on the Company's website at
INDIVIOR PLC (THE COMPANY ) ANNUAL REPORT AND ACCOUNTS FOR THE YEAR-ENDED DECEMBER 31, 2017 ( ANNUAL REPORT AND ACCOUNTS OR ANNUAL REPORT ) AND 2018 ANNUAL GENERAL MEETING ( AGM ) The Company has today
More informationAllergan Reports Fourth Quarter 2014 Operating Results
Allergan Reports Fourth Quarter 2014 Operating Results IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended December 31, 2014.Allergan also
More informationPay-For-Delay & Stock Prices: Smoking Gun Or Damp Squib?
Pay-For-Delay & Stock Prices: Smoking Gun Or Damp Squib? By Pierre Y. Cremieux, Ted Davis, Mark J. Lewis and Paul E. Greenberg; Analysis Group, Inc. Law360, New York (August 24, 2016, 10:46 AM ET) Pierre
More informationRISK FACTOR ACKNOWLEDGEMENT AGREEMENT
RISK FACTOR ACKNOWLEDGEMENT AGREEMENT Risk Factors. AN INVESTMENT IN FROG PERFORMANCE, LLC. INVOLVES HIGH RISK AND SHOULD BE CONSIDERED ONLY BY PURCHASERS WHO CAN AFFORD THE LOSS OF THE ENTIRE INVESTMENT.
More informationRECENT CASES OFFER INCREASED PROSPECTS FOR MERGERS BY COMPETING HOSPITALS
RECENT CASES OFFER INCREASED PROSPECTS FOR MERGERS BY COMPETING HOSPITALS July 19, 2016 Recent setbacks experienced by the Federal Trade Commission (FTC) in hospital merger challenges may embolden hospitals
More informationThe economics of Pay for Delay cases
The economics of cases Brussels, Dr. Matthew Bennett Vice President, CRA 1 Features of the pharma sector Main players Pharmaceutical companies that are active in research for new compounds (originators)
More informationAmerica Invents Act and Intellectual Property Valuation
April 17, 2012 Webinar Presented By Robert F. Reilly, CPA Chicago, Illinois rfreilly@willamette.com America Invents Act and Intellectual Property Valuation Chicago, Illinois Atlanta, Georgia Portland,
More informationTeva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019
Teva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationJAMISONPRO APPLICATION INTELLECTUAL PROPERTY LAWYERS PROFESSIONAL LIABILITY INSURANCE NOTICE: THIS IS AN APPLICATION FOR A CLAIMS MADE POLICY
Insurer: CNA Insurance Companies CNA Plaza Chicago, IL 60685 JAMISONPRO APPLICATION INTELLECTUAL PROPERTY LAWYERS PROFESSIONAL LIABILITY INSURANCE NOTICE: THIS IS AN APPLICATION FOR A CLAIMS MADE POLICY
More informationPharmaceutical Sector in Brazil Eli Lilly do Brasil Ltda. GSK / Novartis
Pharmaceutical Sector in Brazil Eli Lilly do Brasil Ltda. GSK / Novartis Tereza Cristine Almeida Braga Senior Advisor Tribunal of the Administrative Council for Economic Defense Manta, November 2015 Case
More informationMarketing and Advertising Injuries Are You Covered? January 22, 2014 Los Angeles, California. Sponsored by K&L Gates LLP
[add logo of sponsor] Marketing and Advertising Injuries Are You Covered? January 22, 2014 Los Angeles, California ed by K&L Gates LLP Panelists: Seth A. Gold and David P. Schack #IHCC12 1 Panelists Seth
More informationBraj Aggarwal, CPA, P.C. Certified Public Accountants 120 Bethpage Road Suite 304 Hicksville, NY Phone Fax:
JSW Steel Holding (USA) Inc. Stand-alone Financial Statements For the Years Ended March 31, 2016 and 2015 Braj Aggarwal, CPA, P.C. Certified Public Accountants 120 Bethpage Road Suite 304 Hicksville, NY
More information(period: January-December 2016)
EUROPEAN COMMISSION Competition DG 1. Introduction 8 th Report on the Monitoring of Patent Settlements (period: January-December 2016) Published on 9 March 2018 (1) As announced in the Commission's Communication
More informationPatents and the Polymorph
Patents and the Polymorph Washington, DC (Henry Stuart publ., Feb. 2004) Pharmaceutical Patent Attys, LLC 1 Economic Importance Revenue loss to innovator firms: $51,508,000,000 Revenue gain to generic
More informationIndian Healthcare Industry
Indian Healthcare Industry 2012 Synopsis Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics Pvt. Ltd. (Gyan). While
More informationAn Economic Assessment of Patent Settlements in the Pharmaceutical Industry
Annals of Health Law Volume 19 Issue 2 Winter 2010 Article 5 2010 An Economic Assessment of Patent Settlements in the Pharmaceutical Industry Bret Dickey Compass Lexecon Jonathan Orszag Compass Lexecon
More informationAntitrust/Competition
Antitrust/Competition Key Contacts Steven E. Bizar Partner Philadelphia +1 215 994 2205 Michael L. Weiner Partner New York +1 212 698 3608 Translate Page MENU Cartel Investigations Merger Clearance Merger
More informationTO ACHIEVE CLOSURE OF THE HATCH-WAXMAN ACT S LOOPHOLES, LEGISLATIVE ACTION IS UNNECESSARY: GENERIC MANUFACTURERS ARE ABLE TO HOLD THEIR OWN
TO ACHIEVE CLOSURE OF THE HATCH-WAXMAN ACT S LOOPHOLES, LEGISLATIVE ACTION IS UNNECESSARY: GENERIC MANUFACTURERS ARE ABLE TO HOLD THEIR OWN I. INTRODUCTION...776 II. THE HATCH-WAXMAN ACT...778 A. Enactment
More informationJazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination. Bruce Cozadd, Chairman and CEO
Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination Bruce Cozadd, Chairman and CEO Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform
More informationInvestor Q&A. Q: When will the acquisition be completed?
Q: When will the acquisition be completed? Investor Q&A A: The acquisition is expected to be completed in the second quarter of 2017, subject to the satisfaction of certain customary conditions. The following
More informationSidoti & Company Fall 2017 Conference
Sidoti & Company Fall 2017 Conference September 28, 2017 This presentation is subject to and should be read in conjunction with the disclaimers and other statements contained on the last page of this presentation
More informationInvestment Bulletin May-2018
Investment Bulletin May-2018 MetLife Managed Wealth Portfolio - Foundation Investment Objective The aim of the fund is to manage volatility at or around 5% and to seek a total return. The volatility management
More informationCanada: provisional implementation of trade agreement with EU is delayed to Fall 2017 due to dairy, pharmaceuticals and ISDS disputes
26 July 2017 Indirect Tax Alert News from Americas Tax Center Canada: provisional implementation of trade agreement with EU is delayed to Fall 2017 due to dairy, pharmaceuticals and ISDS disputes EY Global
More informationINSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Acasti Pharma (Nasdaq/ACST) BUY
More informationUnited States: Merger Control
The In-House Lawyer: Comparative Guides United States: Merger Control inhouselawyer.co.uk/index.php/practice-areas/merger-control/united-states-merger-control/ 9/12/2016 This country-specific Q&A provides
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationF I N A N C I A L S T A T E M E N T S
FINANCIAL STATEMENTS AKZO NOBEL ANNUAL REPORT 2003 77 Summary of Significant Accounting Policies Consolidation The consolidated financial statements include the accounts of Akzo Nobel N.V. and its subsidiaries.
More informationThe Commission s Lundbeck Decision: A Critical Review of the Commission s Test For Patent Settlement Agreements
The Commission s Lundbeck Decision: A Critical Review of the Commission s Test For Patent Settlement Agreements James Killick, Jérémie Jourdan & Jerome Kickinson (White & Case, Brussels) 1 1 Introduction
More informationDiscussion Points. Presented by the Business and Industry Advisory Committee (BIAC) to the OECD Competition Committee
The Voice of OECD Business Discussion Points Presented by the Business and Industry Advisory Committee (BIAC) to the OECD Competition Committee Roundtable on Generic Pharmaceuticals October 22, 2009 I.
More informationDefensive Strategies to Avoid Litigation and When Litigation is Unavoidable. Jennise Walker Stubbs Kelsey Copeland
Defensive Strategies to Avoid Litigation and When Litigation is Unavoidable Jennise Walker Stubbs Kelsey Copeland General Tips to Avoid Litigation Determine risk (regulatory and litigation) Do not be
More informationHealth and Pharmaceuticals Committee: Recent Developments Series. September 13, :00 PM EDT. White & Case LLP
Health and Pharmaceuticals Committee: Recent Developments Series June, July, and August 2013 September 13, 2013 12:00 PM EDT White & Case LLP Agenda Patent Settlements Robinson-Patman Act Delayed Generic
More informationNASD Investor Education Foundation
Applied Research & Consulting LLC 320 West 13th Street Seventh Floor NYC, NY 10014 Tel. 212.226.1007 Fax. 212.226.0240 E-mail. arc@arcllc.com NASD Investor Education Foundation Military Personnel and Spouses
More information6th Report on the Monitoring of Patent Settlements (period: January-December 2014)
EUROPEAN COMMISSION Competition DG 1. Introduction 6th Report on the Monitoring of Patent Settlements (period: January-December 2014) Published on 2 December 2015 (1) As announced in the Commission's Communication
More informationAt a glance dechert.com
At a glance Attorney advertising. Prior results do not guarantee a similar outcome. Dechert is a global specialist law firm. Focused on sectors with the greatest complexities, legal intricacies and highest
More information1983 M.S., Engineering-Economic Systems, Stanford University B.S., Mathematics/Computer Science, Duke University
DAVID A. FENICHEL Executive Vice President Compass Lexecon 1999 Avenue of the Stars, Suite 1150 Los Angeles, CA 90067 phone 310.728.2049 fax 310.728.2070 EDUCATION 1986 M.A., Economics, Stanford University
More informationSession 74PD: Valuation and Reporting of Non- Guaranteed Elements
Session 74PD: Valuation and Reporting of Non- Guaranteed Elements Moderator: James A. Miles, FSA, MAAA Presenters: Curtis Matthew Clingerman, FSA, MAAA Terryn James Boucher, FSA, MAAA August 28, 2018 SOA
More informationIMPORTANT TERMS OF OUR HOME EQUITY LINE OF CREDIT PROGRAMS
IMPORTANT TERMS OF OUR HOME EQUITY LINE OF CREDIT PROGRAMS Bay State Savings Bank is proud to offer the Home Equity Line of Credit solution that fits your needs. This disclosure contains important information
More information9. IP and antitrust 52
9. IP and antitrust 52 Implications of recent cases and likely policy developments in 2017 Rewards for innovation through the existence and protection of intellectual property (IP) rights are crucial in
More informationCase 1:16-cv UNA Document 1 Filed 05/20/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00377-UNA Document 1 Filed 05/20/16 Page 1 of 11 PageID #: 1 Lotus Pharmaceutical Co., Ltd. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE Plaintiff, v. Glaxosmithkline LLC
More informationITURAN LOCATION AND CONTROL LTD. (Exact name of Registrant as specified in its charter and translation of Registrant s name into English)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationPre-Merger Notification India
Updated: August 2006 Copyright Lex Mundi Ltd. 2006 Pre-Merger Notification India Is there a regulatory regime applicable to mergers and similar transactions? Mergers and acquisitions ( combinations ) are
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Biofrontera (Nasdaq/BFRA) BUY
More informationEU, COMPETITION AND REGULATED MARKETS. The General Court Annuls Commission Decision on UPS- TNT Merger. by Marco Hickey
EU, COMPETITION AND REGULATED MARKETS The General Court Annuls Commission Decision on UPS- TNT Merger by Marco Hickey The General Court Annuls Commission Decision on UPS-TNT Merger 15th March 2017 by Marco
More informationINTELLIGENT SYSTEMS CORPORATION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationShareholder Litigation Involving Acquisitions of Public Companies
Economic and Financial Consulting and Expert Testimony Shareholder Litigation Involving Acquisitions of Public Companies Review of 2017 M&A Litigation Introduction This report examines litigation challenging
More informationMarket Report M&A Market Snapshot Q2 2018
Market Report M&A Market Snapshot Q2 2018 New York Boston Chicago Orlando Philadelphia Princeton www.mpival.com Table of Contents Total U.S. Market Activity Overview... 1 Transaction Multiples... 3 Private
More informationFOOTSTAR, INC. and SUBSIDIARY COMPANIES. SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2011
More informationAnnual Report and Accounts for the year ended December 31, 2016 ( Annual Report & Accounts 2016 ) and Annual General Meeting 2017 ( AGM )
Indivior PLC ( Indivior or the Company ) Annual Report and Accounts for the year ended December 31, 2016 ( Annual Report & Accounts 2016 ) and Annual General Meeting 2017 ( AGM ) The Company has today
More informationProfitable Growth : Why Acquisitions Matter at Least in Some Industries
Profitable Growth : Why Acquisitions Matter at Least in Some Industries SAMBA plus SAM-Talk: Zurich, 29 th of April 2014 By: Dr. Thomas W. Schrepfer, MBA, LL.M. 1 Agenda 1 Profitable Growth 2 3 4 Organic
More informationIN THE UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT
14-4624 IN THE UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT PEOPLE OF THE STATE OF NEW YORK, by and through ERIC T. SCHNEIDERMAN, Attorney General of the State of New York, v. Plaintiff-Appellee,
More informationCOCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2018
ASX Announcement 19 February 2019 COCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2018 The business delivered an increase in in sales revenue of 11% and net profit of 16% for the half Reported
More informationRecent Government Enforcement Actions and Private Antitrust Litigation Arthur N. Lerner Christine L. White
Antitrust Action: New Enforcement Moves in the Health Care Arena Recent Government Enforcement Actions and Private Antitrust Litigation Arthur N. Lerner Christine L. White Recent Government Enforcement
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:11-cv-00569-LPS Document 6 Filed 08/15/11 Page 1 of 8 PageID #: 87 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PFIZER IRELAND PHARMACEUTICALS, WARNER-LAMBERT COMPANY,
More informationPrivate Company D&O Exposures. March Sponsored by:
Private Company D&O Exposures March 2013 Private Company D&O Exposures Owners, board members and executives of private companies often question whether their exposures warrant purchasing D&O insurance.
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Sonoma Pharmaceuticals (Nasdaq/SNOA)
More informationJCT/CIMAR 2016 Construction Industry Model Arbitration Rules 2016
JCT/CIMAR 2016 Construction Industry Model Arbitration Rules 2016 2016 Published June 2016 by Thomson Reuters (Professional) UK Limited, trading as Sweet & Maxwell, Friars House, 160 Blackfriars Road,
More informationPay-for-Delay with Settlement Externalities
Pay-for-Delay with Settlement Externalities Emil Palikot and Matias Pietola June 11, 2017 Abstract This paper studies settlements between an incumbent patent holder and multiple potential entrants to the
More informationForward Pharma (NASDAQ:FWP) Corporate Update Jefferies 2017 Global Healthcare Conference. June 6, 2017
Forward Pharma (NASDAQ:FWP) Corporate Update Jefferies 2017 Global Healthcare Conference June 6, 2017 Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward-Looking Statements Certain statements in
More informationProfitable Growth : Why Acquisitions Matter at Least in Some Industries By: Dr. Thomas W. Schrepfer MBA, LL.M. PMIC Advisors Group Ltd.
Profitable Growth : Why Acquisitions Matter at Least in Some Industries By: Dr. Thomas W. Schrepfer MBA, LL.M. PMIC Advisors Group Ltd. Reference: SAMBA plus (Swiss Association of MBAs) SAM-Talk: Zurich,
More informationreporter 2017 Analysis ON PTAB contested proceedings introduction
edition 3 no. reporter NEW SURVEY 2017 Analysis ON PTAB contested proceedings postgranthq.com fitzpatrick, cella, harper & scinto introduction Fitzpatrick, Cella, Harper & Scinto undertook this Report
More informationEvergreening under the Patented Medicines (Notice of Compliance) Regulations
Evergreening under the Patented Medicines (Notice of Compliance) Regulations Drug Patents: The Latest Legal, Policy and Strategic Developments, Insight Information Co. Marriott Downtown Hotel, 475 Yonge
More informationReNeuron Group. US exclusivity deal - more than non-dilutive cash. FY18 results: Strong cash balance. Funded for a busy programme
ReNeuron Group US exclusivity deal - more than non-dilutive cash FY18 results Pharma & biotech ReNeuron ended FY18 with a healthy cash balance and the 11 July announcement of an exclusivity agreement worth
More information4th Report on the Monitoring of Patent Settlements (period: January-December 2012)
EUROPEAN COMMISSION Competition DG 4th Report on the Monitoring of Patent Settlements (period: January-December 2012) Published on 9 December 2013 1. Introduction (1) As announced in the Commission's Communication
More informationCase 1:15-cv UNA Document 1 Filed 11/05/15 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 115-cv-01025-UNA Document 1 Filed 11/05/15 Page 1 of 14 PageID # 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NOVARTIS PHARMACEUTICALS CORPORATION, NOVARTIS AG, NOVARTIS PHARMA
More information